Home Biosimilar Antibodies Protein Tyrosine Kinase HER2 -EGFR Disitamab vedotin
For research use only. Not for use in humans.

Disitamab vedotin

Synonyms: RC-48, RC 480-ADC

Disitamab Vedotin (RC-48 ,RC 480-ADC) is an antibody-drug conjugate(ADC) composed of anti-[ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] humanized monoclonal antibody, conjugated to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Disitamab Vedotin has the potential for use in solid tumors mainly in advanced breast cancer.

Disitamab vedotin

CAS No. 2136633-23-1

Click to purchase products related to Disitamab vedotin

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: D404901 Purity: 99.17% Protein concentration: 3.3mg/ml Endotoxin Level: ＜1EU/mg
99.17

Specificity

Name Citation HER2 Others
Canertinib (CI-1033) 51 EGFR
CP-724714 109
Sapitinib (AZD8931) 50 ErbB3,EGFR
CUDC-101 23 EGFR,HDAC,HDAC1
Mubritinib (TAK 165) 41
AEE788 (NVP-AEE788) 16 EGFR,c-Abl,FLT1
AC480 (BMS-599626) 12 HER1,HER4
TAK-285 5 EGFR/HER1,HER4,MEK1
Tyrphostin AG 879 3 Trk
Tuxobertinib (BDTX-189) 3 EGFR,RIPK2,BLK
Epertinib hydrochloride 1 EGFR,HER4
TAS0728 1
Tyrphostin AG-528 0 EGFR
SU5204 1 VEGFR-2
Pyrotinib dimaleate 6 EGFR
Poziotinib (NOV120101, HM781-36B) 37 HER1,HER4
HER2-Inhibitor-1 1
Zongertinib (BI 1810631) 1 EGFR-Ex20ins
Nordihydroguaiaretic acid (NDGA) 2 p300,IGF-1R,lipoxygenase
EGCG ((-)-Epigallocatechin Gallate) 42 FASN,EGFR,DNMT
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Disitamab Vedotin (RC-48 ,RC 480-ADC) is an antibody-drug conjugate(ADC) composed of anti-[ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] humanized monoclonal antibody, conjugated to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Disitamab Vedotin has the potential for use in solid tumors mainly in advanced breast cancer.
References

Product Details

CAS No. 2136633-23-1
DAR 3.8
ADC antiody Disitamab
ADC cytotoxin MMAE
Formulation 1xPBS
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06417554 RECRUITING Drug: SHR-A2102|Drug: SHR-A2102 ; Adebrelimab injection|Drug Advanced Solid Tumors Shanghai Hengrui Pharmaceutical Co., Ltd. 2024-05-27 PHASE1; PHASE2
NCT06278870 RECRUITING Drug: disitamab vedotin|Drug: Pyrotinib|Drug: trastuzumab|Dr HER2-positive Metastatic Breast Cancer; First-line Treatment Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2023-09-06 PHASE3
NCT07474064 NOT_YET_RECRUITING Drug: Probiotic|Drug: Disitamab Vedotin|Drug: Toripalimab Muscle Invasive Bladder Cancer (MIBC) chenxu 2026-03-26 PHASE2
NCT07608224 NOT_YET_RECRUITING Drug: Disitamab Vedotin (RC48)|Drug: Gemcitabine + Cisplatin Urinary Bladder Neoplasms West China Hospital 2026-06-20 PHASE2; PHASE3
NCT07207824 RECRUITING Drug: Active Comparator: BCG induction and maintenance|Drug: Bladder (Urothelial, Transitional Cell) Cancer; NMIBC Fudan University 2025-12-01 PHASE3
NCT06157892 ACTIVE_NOT_RECRUITING Drug: disitamab vedotin|Drug: tucatinib Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Metastatic Breast Cancer; Metastatic Gastric Cancer; Advanced Breast Cancer; Advanced Gastric Cancer Seagen, a wholly owned subsidiary of Pfizer 2024-05-20 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-24)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.